Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma

Lung Cancer ◽  
2014 ◽  
Vol 85 (2) ◽  
pp. 161-167 ◽  
Author(s):  
Ji-Youn Han ◽  
Sun Hye Kim ◽  
Yeon-Su Lee ◽  
Seung-Youn Lee ◽  
Jung-Ah Hwang ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Targeted Next Generation Sequencing ◽  
Epidermal Growth ◽  
Never Smokers ◽  
Egfr Tki ◽  
Generation Sequencing ◽  
Conventional Sequencing

scholarly journals Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

RSC Advances ◽  
2018 ◽  
Vol 8 (70) ◽  
pp. 40387-40394 ◽  
Author(s):  
Mohamed W. Attwa ◽  
Adnan A. Kadi ◽  
Hany W. Darwish ◽  
Ali S. Abdelhameed
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Third Generation ◽  
Epidermal Growth ◽  
Egfr Tki

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

scholarly journals Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor

2016 ◽  
Vol 11 (1) ◽  
pp. 427-431
Author(s):  
Lingling Zhang ◽  
Xiaoxue Zhang ◽  
Liang Zhao
Keyword(s):  
Drug Resistance ◽  
Epidermal Growth Factor Receptor ◽  
Signaling Pathway ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Egfr Signaling ◽  
Egfr Signaling Pathway ◽  
Epidermal Growth ◽  
Egfr Tki

AbstractThe EGFR signaling pathway plays an important role in the occurrence and development of many malignant tumors. It has become a hot spot in the treatment of advanced cancer. At present, the small molecule epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been shown to advanced non-small-cell lung cancer (NSCLC), has a marked drug resistance or has developed one. The EGFR signaling pathway regulates a variety of cellular functions, and its drug resistance may be related to a number of signal transduction pathways, including drug resistance mutations, structural activation, downstream signaling pathway activation and VEGF expression changes, and so on. In this paper, we review the production mechanism of EGFR-TKI drug resistance.

Sign in / Sign up

Export Citation Format

Share Document